Prognostic factors of immunotherapy in metastatic renal cell carcinoma

被引:0
|
作者
Peeter Padrik
机构
[1] Tartu University Clinics,Clinic of Hematology & Oncology
来源
Medical Oncology | 2003年 / 20卷
关键词
Kidney neoplasms; immunotherapy; biological response modifiers; prognosis; risk;
D O I
暂无
中图分类号
学科分类号
摘要
The prognosis of the majority of patients with metastatic renal cell carcinoma is poor, and there is no internationally recognized standard therapy for these patients. Patients are treated with interferon alpha or interleukin-2 monotherapy, or combinations outside of clinical trials and a subgroup of patients responds to these therapies. Because immunotherapy induces adverse effects in almost every patient, it is necessary to avoid treating patients who will not, in the end, benefit from the treatment. It is therefore sensible to carefully select patients prior to the initiation of immunotherapy. Determining prognostic factors of survival or of rapid progression under treatment would be of help for selecting patients for immunotherapy. This article reviews current data about prognostic and predictive factors from immunotherapy studies in metastatic renal cell carcinoma comparing all analyzed factors with those that demonstrated an independent prognostic significance in multivariate analyses.
引用
收藏
页码:325 / 334
页数:9
相关论文
共 50 条
  • [1] Prognostic factors of immunotherapy in metastatic renal cell carcinoma
    Padrik, P
    [J]. MEDICAL ONCOLOGY, 2003, 20 (04) : 325 - 334
  • [2] Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma
    van Herpen, CML
    De Mulder, PHM
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 41 (03) : 327 - 334
  • [3] PROGNOSTIC FACTORS OF METASTATIC RENAL CELL CARCINOMA PATIENTS IN THE IMMUNOTHERAPY ERA
    La Russa, F.
    Riolfi, M.
    Sava, T.
    Ghimenton, C.
    Porcaro, A.
    Cesaro, G.
    Consoli, F.
    Manno, P.
    Pavarana, M.
    Cetto, G. L.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 197 - 197
  • [4] The use of prognostic factors in metastatic renal cell carcinoma
    Li, Haoran
    Samawi, Haider
    Heng, Daniel Y. C.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (12) : 509 - 516
  • [5] Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma
    Kwak, Cheol
    Park, Yong Hyun
    Jeong, Chang Wook
    Jeong, Hyeon
    Lee, Sang Eun
    Moon, Kyung Chul
    Ku, Ja Hyeon
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (04) : 317 - 323
  • [6] Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma
    Kwak, Cheol
    Park, Yong Hyun
    Jeong, Chang Wook
    Jeong, Hyeon
    Lee, Sang Eun
    Ku, Ja Hyeon
    [J]. TUMORI JOURNAL, 2007, 93 (01): : 68 - 74
  • [7] Immunotherapy in metastatic renal cell carcinoma
    Rohrmann, K
    Staehler, M
    Haseke, N
    Bachmann, A
    Stief, CG
    Siebels, M
    [J]. WORLD JOURNAL OF UROLOGY, 2005, 23 (03) : 196 - 201
  • [8] Immunotherapy of metastatic renal cell carcinoma
    McDermott, David F.
    Atkins, Michael B.
    [J]. CANCER JOURNAL, 2008, 14 (05): : 320 - 324
  • [9] Immunotherapy for metastatic renal cell carcinoma
    Unverzagt, Susanne
    Moldenhauer, Ines
    Nothacker, Monika
    Rossmeissl, Dorothea
    Hadjinicolaou, Andreas V.
    Peinemann, Frank
    Greco, Francesco
    Seliger, Barbara
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (05):
  • [10] Immunotherapy for metastatic renal cell carcinoma
    McDermott, David F.
    Rini, Brian I.
    [J]. BJU INTERNATIONAL, 2007, 99 (05) : 1282 - 1288